Barclays PLC Trims Position in Indivior PLC (NASDAQ:INDV)

Barclays PLC lessened its stake in Indivior PLC (NASDAQ:INDV - Free Report) by 63.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 772,380 shares of the company's stock after selling 1,358,522 shares during the quarter. Barclays PLC owned 0.56% of Indivior worth $9,599,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Indivior during the 4th quarter worth approximately $56,000. Stifel Financial Corp acquired a new position in shares of Indivior during the 3rd quarter valued at about $100,000. Rathbones Group PLC lifted its position in Indivior by 11.6% in the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after buying an additional 1,483 shares during the last quarter. Jane Street Group LLC acquired a new position in Indivior in the third quarter valued at about $180,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Indivior during the fourth quarter worth about $359,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Wall Street Analyst Weigh In

INDV has been the topic of a number of recent research reports. Rodman & Renshaw started coverage on shares of Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target on the stock. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Finally, Piper Sandler reduced their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th.

Indivior Stock Performance

INDV traded up $0.01 on Monday, hitting $11.57. 1,437,264 shares of the company were exchanged, compared to its average volume of 972,277. The business's fifty day moving average is $9.49 and its 200 day moving average is $10.37. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $18.59. The firm has a market capitalization of $1.60 billion, a P/E ratio of -33.06 and a beta of 0.93.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $240.13 million. Analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.